The nitrogen (N₂) single-breath washout (SBW) test is a measure of ventilation distribution inhomogeneity and also a small airway function that offers complementary information to spirometry; however, the relevance to the forced oscillation technique (FOT) and pulmonary emphysema in COPD is not fully understood. We hypothesized that pulmonary functions, forced oscillatory parameters, and emphysema extent would contribute independently to the results of the SBW test. In this cross-sectional study we assessed the relationship between the phase III slope (delta N₂) derived from N₂ SBW and these parameters. Spirometry, lung volumes, N₂ SBW, and the broadband frequency FOT were performed in 56 patients with COPD. Emphysema extent was measured by high-resolution computed tomography and scored. In multiple regression analyses, the delta N₂ was independently predicted by forced vital capacity, resonant frequency, and emphysema score (R(2)=0.57, p<0.0001). The degree of ventilation inhomogeneity derived from N₂ SBW is independently predicted by spirometry, lung mechanics, and the degree of emphysema.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.resp.2013.06.018DOI Listing

Publication Analysis

Top Keywords

phase iii
8
iii slope
8
single-breath washout
8
sbw test
8
emphysema extent
8
delta n₂
8
n₂ sbw
8
n₂
5
predictors phase
4
slope nitrogen
4

Similar Publications

Introduction: The use of taxanes in the adjuvant setting of early breast cancer (BC) confers survival benefits, however, their role in older patients merits further study. This retrospective pooled analysis of randomized controlled trials conducted by the Hellenic Oncology Research Group (HORG) aims to assess the efficacy and safety of taxane-based adjuvant chemotherapy in older women with BC.

Materials And Methods: Five phase III trials containing a taxane, conducted by HORG between 1995 and 2013, were included in a patient-data pooled analysis.

View Article and Find Full Text PDF

Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.

Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Mayo Clinic, Rochester, MN, USA.

Background: Phase four of the Alzheimer's Disease Neuroimaging Initiative (ADNI4) began in 2023. This time-period corresponded to MRI vendors introducing product sequences with compressed sensing (CS), cross-vendor adoption of arterial spin-labelling (ASL) and multi-band slice excitation, and hardware improvements (head-coils, increased gradient amplitudes). These advances enabled the acquisition of new imaging measures and reduced scan times.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of (South).

Background: We aimed to investigate whether the quantitative analysis of plasma biomarkers could distinguish the pathology stages indicated by positron emission tomography (PET)-based Thal phase of amyloid and Braak stage of tau.

Method: A total of 232 participants were enrolled, all of whom underwent F-florbetaben (FBB), F-flortaucipir (FTP) PET, plasma p-tau217/np-tau217 ratio, p-tau217, and Aβ ratio. To differentiate between image-based Thal phases and Braak stages, region-of-interests (ROIs) were constructed, and cut-off points were established at each stage using Gaussian mixture modeling.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!